Reaction

Small Intestinal Perforation reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,855 reports · 59 co-occurring drugs

As of the last recalculation, Small Intestinal Perforation appears in 1,855 FAERS reports alongside 59 co-occurring drug terms. The strongest observed disproportionality signal is BEVACIZUMAB (PRR 27.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Bevacizumab	259	27.1	27.2
Polatuzumab Vedotin	21	24.4	24.5
Basiliximab	25	24.2	24.2
Lenvatinib	68	24.1	24.2
Irinotecan Hydrochloride	22	19.4	19.4
Febuxostat Tablets 40 Mg	17	18.9	19.0
Febuxostat Tablets 80 Mg	17	18.9	19.0
Axicabtagene Ciloleucel	14	16.0	16.1
Amphotericin B	17	15.4	15.4
Pembrolizumab	128	14.6	14.6
Dexamethasone Sodium Phosphate	12	13.3	13.4
Pemetrexed Disodium	43	12.9	13.0
Theophylline	13	12.8	12.8
Theophylline Anhydrous	13	11.8	11.9
Paclitaxel (Aibumin-Bound)	83	11.8	11.8
Febuxostat	17	11.5	11.5
Paclitaxel	95	11.3	11.3
Loperamide Hydrochloride Oral	10	11.0	11.1
Leucovorin Calcium	18	10.7	10.7
Carboplatin	111	10.4	10.4
Doxorubicin	76	9.9	9.9
Fluorouracil	66	9.9	9.9
Fluorouracil Cream, 0.5%	65	9.9	9.9
Oxaliplatin	63	9.8	9.8
Anti-Thymocyte Globulin (Rabbit)	7	9.8	9.8
Prednisolone	138	9.2	9.2
Prednisolone Oral	138	9.2	9.2
Prednisolone Oral Solution	138	9.2	9.2
Pemetrexed	17	9.0	9.0
Loperamide Hcl	10	8.8	8.8
Gemcitabine	30	8.7	8.7
Gemcitabine Hydrochloride	39	8.4	8.4
Obinutuzumab	12	8.2	8.2
Atezolizumab	27	7.9	7.9
Doxorubicin Hydrochloride	22	7.6	7.6
Melphalan	15	7.5	7.5
Vincristine Sulfate	18	6.9	7.0
Ifosfamide	13	6.8	6.8
Melphalan Hydrochloride	15	6.8	6.8
Mesalamine	33	6.7	6.7
Capecitabine	53	6.7	6.7
Pitavastatin Calcium	6	6.6	6.6
Cyclophosphamide Injection, Solution	99	6.6	6.6
Cyclophosphamide	99	6.6	6.6
Cyclophosphamide For Injection	99	6.6	6.6
Trametinib	14	6.5	6.5
Cisplatin	43	6.3	6.3
Durvalumab	11	6.1	6.1
Etoposide	38	5.9	5.9
Cladribine	5	5.9	5.9
Nivolumab	44	5.2	5.2
Cetuximab	14	5.0	5.0
Cabozantinib	21	4.9	5.0
Panitumumab	6	4.3	4.3
Dabrafenib	8	4.3	4.3
Trifluridine And Tipiracil	4	4.2	4.2
Pazopanib Hydrochloride	9	3.7	3.7
Ipilimumab	14	3.7	3.7
Pegfilgrastim	22	2.5	2.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.